Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Account Payables (2018 - 2025)

Serina Therapeutics (SER) has disclosed Change in Account Payables for 8 consecutive years, with -$811000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 14.54% to -$811000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 172.07% year-over-year, with the annual reading at $1.2 million for FY2025, 172.07% up from the prior year.
  • Change in Account Payables hit -$811000.0 in Q4 2025 for Serina Therapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q4 2022 to a low of -$1.4 million in Q2 2024.
  • Historically, Change in Account Payables has averaged -$38789.5 across 5 years, with a median of -$304000.0 in 2021.
  • Biggest five-year swings in Change in Account Payables: soared 473.94% in 2023 and later tumbled 630.0% in 2024.
  • Year by year, Change in Account Payables stood at -$946000.0 in 2021, then skyrocketed by 230.87% to $1.2 million in 2022, then tumbled by 110.5% to -$130000.0 in 2023, then crashed by 630.0% to -$949000.0 in 2024, then grew by 14.54% to -$811000.0 in 2025.
  • Business Quant data shows Change in Account Payables for SER at -$811000.0 in Q4 2025, $1.0 million in Q3 2025, and $522000.0 in Q2 2025.